Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06144840 · ClinicalTrials.gov registry record · Phase 3
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
A Phase 3 study of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP), sponsored by Tanabe Pharma America.
- Active
- Registry status
- Phase 3
- Development phase
- 165
- Enrollment target
- 20
- Study locations
NCT06144840: Active Phase 3 study of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP), sponsored by Tanabe Pharma America.
NCT06144840 is a Phase 3 study of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) that is active but no longer recruiting, run by Tanabe Pharma America. The registered enrollment target is 165 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06144840, a Phase 3 study of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP), is active but no longer recruiting, sponsored by Tanabe Pharma America.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 165 participants
- Enrollment target
- 20
- Study locations
Study Summary
To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.
Primary Outcome
The comparison between MT-7117 treatment group and placebo group will be performed.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dersimelagon
Study Locations (20)
Other
- University Multi-Profile Hospital for Active Treatment (UMHAT) St. Ivan Rilski - Porphyria Center - Sofia
- Institute for Clinical and Experimental Medicine - IKEM - Prague
- Centre Hospitalier Universitaire de Bordeaux - Hopital Saint - Andre - Bordeaux
- CHU Nantes - Nantes
- Hôpital Bichat - Hospital Bichat-Hopitaux Universitaires Paris Nord Val de Seine - Paris
- Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Louis-Mourier - Paris
California
- Marvel Clinical Research, LLC - Huntington Beach
- University of California at San Francisco - San Francisco
Massachusetts
- MGH - Boston
- MetroBoston Clinical Partners, LLC - Brighton
Florida
- University Of Miami School Of Medicine, Center For Liver Diseases - Miami
Michigan
- Henry Ford Health System - Detroit
Missouri
- Kansas City Research Institute - Kansas City
New York
- Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH) - New York
North Carolina
- Wake Forest University Baptist Health - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2023-12-11 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
What the registry record for NCT06144840 still lists
NCT06144840 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Erythropoietic Protoporphyria (EPP) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06144840 names 20 study sites across 13 states, led by Other, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06144840 about?
NCT06144840 is a clinical study titled "INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP". To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.
What is the current status of trial NCT06144840?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 165 participants. The study started on 2023-12-11. Estimated completion is 2026-06.
What conditions does trial NCT06144840 study?
This clinical trial studies the following conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP).
What interventions are being tested in trial NCT06144840?
The interventions under investigation include: Placebo (DRUG), Dersimelagon (DRUG).
Who is sponsoring clinical trial NCT06144840?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06144840 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erythropoietic Protoporphyria (EPP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06144840's enrollment target sits among peer trials
165 1466th of 2000 higher than 531 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI